Oncology News

Details from a recently published review discussed expanded use of alcohol use disorder medications and treatments in everyday clinical practice for patients with advanced liver disease.

Caner rates continue to increase worldwide, including gastrointestinal and hepatic carcinomas. As the need for improved therapies and potential curative options increases, researchers have focused their efforts to determine demographic risk factors, incidence probabilities, and survival outcomes.

Results of an international systematic review showed that patients and their families had a poor understanding about advanced liver disease, felt they needed more information about treatments and how to get practical and psychological support, and were unaware of the potential for palliative care.

Analysis of hepatocellular carcinoma risk factors among patients with varying hepatitis B surface antigen status showed that higher BMI was a risk factor among those with HBsAg seroclearance compared with those with persistent HBsAg positivity.

A recently developed liquid biopsy cell-sorting device was able to detect circulating epithelial cells of hepatocyte origin in blood from healthy individuals, patients with chronic liver disease without hepatocellular cancer, and those with HCC, according to a recently published study.

An estimated 18.1 million new cancer cases will be diagnosed worldwide in 2018, according to a report released today by International Agency for Research on Cancer.

Intratumoral tertiary lymphoid structures correlated with a lower risk for early relapse of hepatocellular carcinoma after surgical resection, according to data published in Journal of Hepatology.

In this guest commentary from the Liver Health Initiative, Thelma King Thiel, RN, BA, former CEO of both the American Liver Foundation and the Hepatitis Foundation International, gives insight into speaking with pediatric patients and parents about liver health. After losing her son to biliary atresia, Thiel focused on training health care providers about liver health. She recently founded the Liver Health Initiative to continue to fill the knowledge gap that exists about liver health.

SillaJen and Lee’s Pharmaceutical Holdings announced the first patient enrolled in China in the phase 3 PHOCUS trial Pexa-Vec, an oncolytic immunotherapy for advanced liver cancer, according to a press release.

Results of a pooled analysis and systematic review showed an increased risk for intrahepatic cholangiocarcinoma among patients with obesity and diabetes.